Sun Pharmaceutical Industries and AstraZeneca Pharma India (AZPIL) have entered agreement for distribution of AstraZeneca’s brand “Axcer”, a new brand of ticagrelor in India. This drug is used for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand under the trademark “Brilinta”, for ticagrelor molecule, launched and marketed by AZPIL in India since 2012. This collaboration will provide customers access to this latest generation treatment option for ACS.
Ticagrelor is a blood thinner that may help prevent stroke, heart attack, and other heart and blood vessel problems. Ticagrelor is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Ticagrelor (90mg) is indicated to reduce the rate of thrombotic CV events in patients with ACS (unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]).
In India Sun Pharma will be promoting and distributing “Axcer” brand. It strengthens Sun Pharma’s cardiology portfolio with the addition of a new patented therapy. Sun Pharmaceutical Industries is a multinational pharmaceutical company that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs)
Subscribe to PharmaTutor News Alerts by Email >>
